4 results
Primary Objective:To demonstrate that serelaxin is superior to placebo in reducing CV death in AHF patients during a follow-up period of 180 days.To demonstrate that serelaxin is superior to placebo in reducing worsening heart failure through Day…
Primary:Assess the safety of repeat doses of serelaxin in chronic heart failureSecondary:- Assess the incidence rate of adverse events of special interest, indicative of hypersensitivity reactions- Assess the safety and tolerability of repeated…
The primary objective of this study is to demonstrate the efficacy of fremanezumab in the prevention of CCH in adult patients:- The primary efficacy endpoint of this study is the mean change from baseline (run-in period) in the monthly average…
The primary objective of this study is to demonstrate the efficacy of fremanezumab in the prevention of ECH in adult patients. The primary efficacy endpoint of this study is the mean change from baseline (run-in period) in the weekly average number…